We found, for instance, that 6 cancer-related targets changed their expression levels: HSPD1 (Ghosh et al., 2008), PARP1 (Cipak and Jantova, 2010), XRCC5 (Yang et al., 2008), PRDX2 (Stresing et al., 2013), MTA2 (Cui et al., 2006) and FASN (Zhou et al., 2003) (Fig. 6C). Here, MTA2 is linked to cancer.